Search
Biospace news
RSS Feed for Biotech, Pharmaceutical and Clinical Research News | BioSpace (Generated by New Sloth)
Updated: 18 hours 41 min ago
5 Top Companies Hiring in the Washington, D.C., Area
5 Top Companies Hiring in the Washington, D.C., Area 6/27/2024
Lyell Reports Patient Death in Early-Stage CAR T Trial, Shows Otherwise Strong Response Rate
Lyell Reports Patient Death in Early-Stage CAR T Trial, Shows Otherwise Strong Response Rate 6/26/2024
Zealand to Raise $1B in Public Offering to Fund Obesity Candidates
Zealand to Raise $1B in Public Offering to Fund Obesity Candidates 6/26/2024
Curie.Bio Adds $380M Series A Fund to Move Biotech Startups to Clinic
Curie.Bio Adds $380M Series A Fund to Move Biotech Startups to Clinic 6/26/2024
Lilly Teams With OpenAI to Tackle Threat of Drug-Resistant Bacteria
Lilly Teams With OpenAI to Tackle Threat of Drug-Resistant Bacteria 6/26/2024
Wave Clears Phase Ib/IIa Study in Huntington’s Disease, Eyes Accelerated Approval
Wave Clears Phase Ib/IIa Study in Huntington’s Disease, Eyes Accelerated Approval 6/26/2024
Teva Pays $750M to Resolve Israeli Tax Issues Going Back More Than a Decade
Teva Pays $750M to Resolve Israeli Tax Issues Going Back More Than a Decade 6/26/2024
How Pfizer, Bristol Myers Squibb and Johnson & Johnson Are Confronting Patent Cliffs
How Pfizer, Bristol Myers Squibb and Johnson & Johnson Are Confronting Patent Cliffs 6/26/2024
Sarepta’s Big DMD Approval, Alnylam’s Clinical Win and ADA Highlights
Sarepta’s Big DMD Approval, Alnylam’s Clinical Win and ADA Highlights 6/26/2024
After Full Approval, Sarepta Lays Out Its Next Moves
After Full Approval, Sarepta Lays Out Its Next Moves 6/26/2024
Opinion: Prepare Your Biopharma for the Next Pandemic, for Business and Global Good
Opinion: Prepare Your Biopharma for the Next Pandemic, for Business and Global Good 6/26/2024
5 FDA Decisions to Watch in the Second Half of 2024
5 FDA Decisions to Watch in the Second Half of 2024 6/24/2024
FDA Action Alert: Merck, Verona, AbbVie and Rocket
FDA Action Alert: Merck, Verona, AbbVie and Rocket 6/24/2024
Expanded Approval of Sarepta’s Elevidys Is Progress, But More Needed for DMD Patients
Expanded Approval of Sarepta’s Elevidys Is Progress, But More Needed for DMD Patients 6/21/2024
Zealand Deepens Weight-Loss Portfolio With Strong Phase Ib Data for GLP-1 Alternative
Zealand Deepens Weight-Loss Portfolio With Strong Phase Ib Data for GLP-1 Alternative 6/21/2024
Jazz’s Tremor Drug Candidate Flops in Phase II Study, Misses Primary Endpoint
Jazz’s Tremor Drug Candidate Flops in Phase II Study, Misses Primary Endpoint 6/21/2024
Vertex Finally Reaches Pricing Deal with England’s NHS for Cystic Fibrosis Drug
Vertex Finally Reaches Pricing Deal with England’s NHS for Cystic Fibrosis Drug 6/21/2024
Vanda Turns Down Cycle, Future Pak Offers as Proposals ‘Undervalue’ Company
Vanda Turns Down Cycle, Future Pak Offers as Proposals ‘Undervalue’ Company 6/21/2024
Tectonic Completes Reverse Merger With Avrobio, Starts Trading on Nasdaq
Tectonic Completes Reverse Merger With Avrobio, Starts Trading on Nasdaq 6/21/2024
Sarepta Wins Full Approval and Label Expansion for DMD Gene Therapy
Sarepta Wins Full Approval and Label Expansion for DMD Gene Therapy 6/21/2024
World Pharma News
- Novel drug application shows improved survival for patients with relapsed and refractory acute myeloid leukemia
- Study shows ancient viruses fuel modern-day cancers
- Darolutamide meets primary endpoint in Phase III ARANOTE trial
- Pfizer advances development of once-daily formulation of oral GLP-1 receptor agonist danuglipron
- New AI approach optimizes antibody drugs